Biotech entity
Abbott is most often covered alongside Eli Lilly, which appears in 1 of these 2 stories. That works out to roughly 0.7 stories per week across a 19-day span. They are better corroborated than the beat average, carrying 4.5 original sources each against 3.3 for the same window.
Last mentioned: Mar 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Abbott is most often covered alongside Eli Lilly, which appears in 1 of these 2 stories. That works out to roughly 0.7 stories per week across a 19-day span. They are better corroborated than the beat average, carrying 4.5 original sources each against 3.3 for the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. At 5.5, the average consequence score sits below the same-window beat average of 6. This profile follows 2 Biotech stories mentioning Abbott across the period from February 19, 2026 to March 9, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 211 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Abbott. Shared-story counts are live from our verified record — not editorial picks.
Seveno Capital has announced a strategic investment in PointFit, a biotech startup developing a non-invasive sweat-sensing skin patch. The partnership aims to transition the wearable market from mechanical tracking to real-time biochemical analysis using proprietary nanomembrane technology.
As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
Abbott is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
